%0 Journal Article
%A Fakhouri, Fadi
%A Hourmant, Maryvonne
%A Campistol, Josep M
%A Cataland, Spero R
%A Espinosa, Mario
%A Gaber, A Osama
%A Menne, Jan
%A Minetti, Enrico E
%A Provôt, François
%A Rondeau, Eric
%A Ruggenenti, Piero
%A Weekers, Laurent E
%A Ogawa, Masayo
%A Bedrosian, Camille L
%A Legendre, Christophe M
%T Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
%D 2016
%U http://hdl.handle.net/10668/9943
%X Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-organ damage. Eculizumab, a terminal complement inhibitor approved for aHUS treatment, was reported to improve hematologic and renal parameters in 2 prior prospective phase 2 studies. This is the largest prospective study of eculizumab in aHUS to date, conducted in an adult population. Open-label single-arm phase 2 trial. Patients 18 years or older with aHUS (platelet count  Intravenous eculizumab (900mg/wk for 4 weeks, 1,200mg at week 5 and then every 2 weeks) for 26 weeks. Primary end point was complete TMA response within 26 weeks, defined as hematologic normalization (platelet count ≥150 × 10(3)/μL, LDH ≤ ULN), and preservation of kidney function ( 41 patients were treated; 38 (93%) completed 26 weeks of treatment. 30 (73%) were included during their first TMA manifestation. 30 (73%) had complete TMA response. Platelet counts and estimated glomerular filtration rates increased from baseline (P Single-arm open-label design. Results highlight the benefits of eculizumab in adult patients with aHUS: improvement in hematologic, renal, and quality-of-life parameters; dialysis discontinuation; and transplant protection.
%K Eculizumab
%K Soliris
%K TMA response
%K adults
%K atypical hemolytic uremic syndrome (aHUS)
%K clinical trial
%K hematologic normalization
%K hemoglobin
%K kidney disease
%K lactate dehydrogenase (LDH)
%K platelet count
%K renal function
%K terminal complement inhibitor
%K thrombotic microangiopathy (TMA)
%~